Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUILIBRIX-S: VMX-C001 versus usual pharmacological care for urgent high-bleeding-risk surgery in patients on factor Xa DOACs
2025-521632-12-00Phase 3Authorised
- Sponsor
- VarmX
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of VMX-C001 (2 arms), sponsored by VarmX. Planned start Jul 2026; status: authorised.
02
Drugs
VMX-C001
Beyond the preview
Go deeper on 2025-521632-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521632-12-00.